Natera Reports Strong Revenue Growth in Q3 2024

Natera Inc. ( (NTRA) ) has released its Q3 earnings. Here is a breakdown of the information Natera Inc. presented to its investors.

Natera Inc. is a leading company in the field of cell-free DNA and genetic testing, focusing on oncology, women’s health, and organ health, with a mission to integrate personalized genetic diagnostics into standard healthcare practices. In its recent third quarter of 2024 financial report, Natera announced a significant increase in total revenues, reaching $439.8 million, a 63.9% rise compared to the same period last year. This growth was fueled by a substantial increase in product revenues and test volumes, alongside an improvement in gross margins. Key financial highlights include a gross margin improvement to 61.8% from 45.1% in the previous year and a positive cash flow of approximately $34.5 million. The company processed about 775,800 tests during the quarter, marking a 23.9% increase, with oncology tests growing by 54.4%. Despite incurring a net loss of $31.6 million, Natera reduced its operational losses compared to the previous year. The company also raised its annual guidance, anticipating total revenues between $1.61 billion and $1.64 billion for 2024. Natera’s strategic advancements include the completion of a colorectal cancer study using Signatera and the publication of significant research in Nature Medicine. Looking ahead, Natera remains focused on expanding its market presence and product offerings, while managing operational costs and driving revenue growth.